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Introduction
Type 1 hepatorenal syndrome is
kidney failure that occurs in advanced
cirrhosis (Fagundes & Ginès, 2012). It is
characterized by a, “significant reduction
in creatinine clearance within 1-2 weeks
of presentation” (Bacon, 2015). Patients
that develop this condition have a
median survival rate of one month
(Dameron, 2011). Vasodilation leads to
decreased perfusion to the kidneys and
thus kidney injury (Boyer et al., 2011).
Liver transplantation is the best
treatment for hepatorenal syndrome
(Fagundes & Ginès, 2012). Common
causes of cirrhosis are hepatitis C
infection, alcohol consumption, and fatty
liver disease (Warner, Cuthbert, Bhore,
& Rockey, 2011). Regardless of the
cause of cirrhosis, the progression of
hepatorenal syndrome once identified is
extremely quick and deadly.
According to the National Institute of
Diabetes and Digestive and Kidney
Diseases (2016), cirrhosis is the twelfth
leading cause of death in the United
States and accounted for 36,427 deaths
in 2013. In 2004, the direct costs
associated with cirrhosis in the United
States were $2.5 billion and the indirect
costs were estimated to be $10.6 billion
(Neff, Duncan, & Schiff, 2011). One
estimate places the prevalence of
cirrhosis in the United States at 0.27% of
the population or 644,323 people
(Scaglione et al., 2015). Type 2
hepatorenal syndrome differs from type
1 in that is has a slower onset and is less
severe as well as less deadly. Type 1
hepatorenal syndrome is an acute
condition that develops in a short period
of time (within two weeks). It is
important that diagnosis is timely
because this condition signals likely
fatality in about 30 days (Dameron,
2011). Scaglione et al. (2015) concludes
that many cases of cirrhosis may be
undiagnosed and, “more than half are
potentially preventable by controlling
diabetes, alcohol abuse, and viral
hepatitis” (p. 690). Perhaps, the
dissemination of information to the
general public about the safety concerns
related to obesity, hepatitis
transmission, and alcohol use can
increase self-preventative interventions
and decrease deaths related to liver
disease.

Pathophysiology

Cirrhosis
Though type 1 hepatorenal
syndrome is an acute process, it is
preceded by the chronic development of
liver cirrhosis. Widespread fibrosis of
the liver and the development of
abnormal liver nodules is typically
caused by one of three mechanisms:
•
•
•

Alcoholic liver disease
Hepatitis
Nonalcoholic fatty liver disease

Any of these conditions can lead to
cirrhosis (Perri, 2013).
The effects of advanced liver disease
are many, often comorbid, and
interrelated. They include:
•

Portal hypertension

Esophageal varices
Hypersplenism
Spontaneous bacterial
peritonitis
•
Hepatorenal syndrome
•
Hepatic encephalopathy
•
Coagulopathy
•
Ascites
(Bacon, 2015)
•
•
•

According to Perri (2013),
ascites is the main complication of
cirrhosis and the mean time
period to its development in liver
disease is ten years. Mortality
after diagnosis is estimated at fifty
percent in two years. Ascites is
almost always present in those
that develop hepatorenal
syndrome (Bacon, 2015).

The best evidence suggests that the
kidney dysfunction associated with type
1 hepatorenal syndrome is secondary to
reduced circulatory function (Fagundes &
Ginès, 2012). Cirrhosis is fibrotic
scarring of the liver cells usually caused
by chronic exposure to harmful agents.
This sustained scarring causes reduction
in vascular structure leading to a
condition called portal hypertension
(Møller & Bendtsen, 2015). The two
factors that lead to the development of
portal hypertension are increased
resistance to blood flow through the liver
and splanchnic vasodilation. One of the
most visibly obvious symptoms
associated with portal hypertension is
ascites, accumulation of fluid within the
peritoneal cavity. Ascites is often present
in those that develop hepatorenal
syndrome (Bacon, 2015). Often, the
acute onset of type 1 hepatorenal
syndrome is preceded by a severe
infection known as spontaneous

bacterial peritonitis. One third of those
affected by spontaneous bacterial
peritonitis will develop hepatorenal
syndrome. Severe liver disease is the
underlying chronic condition that leaves
those affected with reduced immunity
and increased susceptibility. With the
presence of ascites, the peritoneal cavity
proves to be a wonderful environment
for bacterial proliferation (Møller &
Bendtsen, 2015). Hepatorenal
syndrome is characterized by increased
vascular resistance in the renal
circulation and reduced vascular
resistance in the peripheral circulation
(Bacon, 2015). This activates the reninangiotensin-aldosterone system with
even further enhancement of renal
vasoconstriction and a severe imbalance
of systemic and renal vasodilation
(Dameron, 2011). There is no direct
problem with the kidneys but rather they
are being deprived of the necessary
perfusion to maintain adequate function.

Management and Implications for Nursing Care
Treatment of type 1 hepatorenal
syndrome can include:
•
•
•
•
•
•

The best option for patients with
type 1 hepatorenal syndrome is a
liver transplant. If performed early
enough, kidney function will likely be
preserved (Fagundes & Ginès, 2012).
The significance of type 1
hepatorenal syndrome should not be
underestimated:
•
•

Process
•
•
•
•
•
•
•
•
Figure 1: Compensated versus decompensated cirrhosis leading to renal
failure (Fagundes & Ginès, 2012)

Inpatient critical care setting
management
The administration of
vasoconstrictors
The administration of albumin
Renal replacement therapy
Transjugular intrahepatic
portosystemic shunt placement
Liver transplant

Cirrhosis is the twelfth leading
cause of death in the United
States (Guirguis et al., 2015)
The costs associated with
cirrhosis are in the billions
annually (Neff, Duncan, & Schiff,
2011)

Exposure to agents such as hepatitis viruses and
alcohol
Liver scarring, loss of function, and loss of normal
vascularity
Increased production of nitric oxide and other
vasodilating substances
Central hypovolemia, caused by “third-spacing”
Widespread splanchnic vasodilation and portal
hypertension leading to ascites
Spontaneous bacterial peritonitis
Renal hypertension, peripheral hypotension, and
reduced kidney perfusion
Type 1 hepatorenal syndrome
Figure 2: Transjugular
intrahepatic portosystemic shunt
(Dameron, 2011)

•

•

Those who do not receive
advanced treatment will likely die
in about thirty days (Dameron,
2011)
Most risk factors for developing
this condition are preventable
(Scaglione et al., 2015)
Primary prevention of type 1
hepatorenal syndrome is directly
related to the prevention of liver
disease. This includes vaccination for
hepatitis B, safe sex practices,
moderation or abstinence of alcohol
intake, and diet and exercise to
control weight. Secondary prevention
would include reduction of alcohol
intake and weight loss. Some tertiary
preventative options include the use
of albumin administration for those
with spontaneous bacterial peritonitis
and the prophylactic administration
of antibiotics in patients at high risk
(Fagundes & Ginès, 2012).

Conclusion
Hepatorenal syndrome type 1 is a
severe and deadly manifestation of end
stage liver disease. It is a direct
consequence of the vasoactive effects
of advanced cirrhosis such as portal
hypertension, splanchnic vasodilation,
and the imbalance of peripheral and
renal bloodflow. Additionally, ascites
with spontaneous bacterial peritonitis
appears to be closely linked with the
development of hepatorenal syndrome
(Møller & Bendtsen, 2015). Though it
is in itself an acute syndrome, the
factors that precipitate the
development of the condition are
mostly preventable. Through
educating patients about the
importance of moderation in alcohol
intake, receiving vaccinations,
maintaining a healthy weight, among
other self care practices, a reduction in
preventable mortality can be achieved.
There are also treatments to slow the
progression and relieve the symptoms
of those affected by cirrhosis.
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